These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31408056)

  • 1. Long-term Vaccine Impact on Invasive Pneumococcal Disease Among Children With Significant Comorbidities in a Large Australian Birth Cohort.
    Jayasinghe S; Liu B; Gidding H; Gibson A; Chiu C; McIntyre P
    Pediatr Infect Dis J; 2019 Sep; 38(9):967-973. PubMed ID: 31408056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010.
    Thoon KC; Chong CY; Tee NW
    Int J Infect Dis; 2012 Mar; 16(3):e209-15. PubMed ID: 22281191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
    Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Childhood Pneumococcal Conjugate Vaccine on Nonnotified Clinically Suspected Invasive Pneumococcal Disease in Australia.
    Gidding HF; Sheridan S; Fathima P; Moore HC; Liu B; McIntyre PB; Palmu AA;
    Pediatr Infect Dis J; 2019 Aug; 38(8):860-865. PubMed ID: 30985507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: An observational study.
    Chan J; Gidding HF; Blyth CC; Fathima P; Jayasinghe S; McIntyre PB; Moore HC; Mulholland K; Nguyen CD; Andrews R; Russell FM
    PLoS Med; 2021 Aug; 18(8):e1003733. PubMed ID: 34343186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent invasive pneumococcal disease in children--host factors and vaccination response.
    Ingels HA
    Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of pneumococcal conjugate vaccine against hospital admissions for pneumonia in Australian children: a retrospective, population-based, record-linked cohort study.
    Fathima P; Gidding HF; McIntyre PB; Snelling TL; McCallum L; de Klerk N; Blyth CC; Liu B; Moore HC
    Lancet Child Adolesc Health; 2019 Oct; 3(10):713-724. PubMed ID: 31439496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric invasive pneumococcal disease in Taiwan following a national catch-up program with the 13-valent pneumococcal conjugate vaccine.
    Wei SH; Chiang CS; Chiu CH; Chou P; Lin TY
    Pediatr Infect Dis J; 2015 Mar; 34(3):e71-7. PubMed ID: 25247584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution.
    Izurieta P; Bahety P; Adegbola R; Clarke C; Hoet B
    Expert Rev Vaccines; 2018 Jun; 17(6):479-493. PubMed ID: 29241390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children.
    van der Linden M; Weiß S; Falkenhorst G; Siedler A; Imöhl M; von Kries R
    Vaccine; 2012 Aug; 30(40):5880-5. PubMed ID: 22771186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease.
    Yildirim I; Shea KM; Little BA; Silverio AL; Pelton SI;
    Pediatrics; 2015 Mar; 135(3):495-503. PubMed ID: 25647674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.
    Jayasinghe S; Chiu C; Menzies R; Lehmann D; Cook H; Giele C; Krause V; McIntyre P
    Vaccine; 2015 Nov; 33(48):6666-74. PubMed ID: 26519550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine.
    Hsu K; Pelton S; Karumuri S; Heisey-Grove D; Klein J;
    Pediatr Infect Dis J; 2005 Jan; 24(1):17-23. PubMed ID: 15665705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease.
    Palmu AA; Kilpi TM; Rinta-Kokko H; Nohynek H; Toropainen M; Nuorti JP; Jokinen J
    Pediatrics; 2015 Jul; 136(1):e22-7. PubMed ID: 26077477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imputing the Direct and Indirect Effectiveness of Childhood Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease by Surveying Temporal Changes in Nasopharyngeal Pneumococcal Colonization.
    Nzenze SA; Madhi SA; Shiri T; Klugman KP; de Gouveia L; Moore DP; Karstaedt AS; Tempia S; Nunes MC; von Gottberg A
    Am J Epidemiol; 2017 Aug; 186(4):435-444. PubMed ID: 28482004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)].
    Artiles F; Horcajada I; Cañas AM; Alamo I; Bordes A; González A; Santana M; Lafarga B
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):14-21. PubMed ID: 19217998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children Before and After the Seven-valent and Thirteen-valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada.
    Ricketson LJ; Conradi NG; Vanderkooi OG; Kellner JD
    Pediatr Infect Dis J; 2018 Jan; 37(1):22-27. PubMed ID: 28737622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.